COMP <GO>
ABBV vs LLY // 10Y YIELD & FRED MACRO BETA
AbbVie Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: ABBV 4
— LLY 11
▲ 10Y YIELD & FRED MACRO BETA LEADER: ABBV
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
macro-sensitivity
1.15
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
macro-sensitivity
0.51
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABBV VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABBV | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 70.20% | 83.64% | -13.44 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.00% | 32.36% | -3.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 33.3x | 36.4x | -3.12 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 3.47% | 2.30% | +1.17 | ABBV | /fcf-yield <GO> |
| Operating Margin | 24.60% | 40.21% | -15.61 | LLY | /operating-margins <GO> |
| Net Profit Margin | 6.90% | 31.90% | -25.00 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 8.60% | 45.51% | -36.91 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.27% | 0.49% | +1.78 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.33 | 9.29 | -3.96 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 6.77% | +0.63 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 72.8 | 77.9 | -5.10 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.15 | 0.51 | +0.64 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 113.1x | 26.3x | +86.85 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $513.86B | $1.33T | -$820.55B | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABBV REV | LLY REV | ABBV GROSS % | LLY GROSS % | ABBV FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $61.16B | $65.18B | 70.2% | 83.0% | $17.82B | $16.81B |
| FY 2024 | $56.33B | $45.04B | 70.0% | 81.3% | $17.83B | $8.82B |
| FY 2023 | $54.32B | $34.12B | 44.0% | 79.3% | $20.39B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABBV // BETA 1.15
LLY // BETA 0.51